Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

McMaster University

$25,000.00

Development of a platform for point-of care testing: Accelerating the Assay Pipeline

FY 2013-14

Summary
Evik Diagnostics proposes to engage with Dr. Sandeep Raha, McMaster University, to validate and transfer rapid assay development technologies that will help the company to accelerate new diagnostic tests to market. With assistance from IRAP, Evik has developed simple, low cost, disposable cartridge tests, with all reagents enclosed, that are suitable for deployment in Africa and other resource limited settings. They are similar to a home pregnancy test in simplicity and stability. The first market target for this test device is the growing HIV/AIDS pandemic. Despite 30 years of development effort we do not yet have an HIV vaccine. Worldwide, 34 million are living with AIDS, and 2.5 million new cases are reported each year. The demand for this test device is enormous with hundreds of millions needing screening for new infection, and people living with retroviral therapy needing repeated monitoring for viral load. The test device will report viral load by HIV p24 concentration plus p24 antibodies in blood, a combination method which has been validated to be faster and simpler than DNA tests but in sensitivity. Using microarray high throughput screening, Dr. Raha's lab will test a library of antibodies to find the optimal pair for highest HIV detection sensitivity, and will provide labeled antibody conjugates for the test device. Dr. Raha's lab will transfer the microarray and conjugate chemistry technologies to Evik and vest these rapid assy development tools in the company so that Evik can quickly bring followup diagnostic tests to market. This alliance of complementary technologies will also foster the development of additional diagnostic assays in the future and promote the Canadian Biotechnology industry.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
461032-2013
Name nom
Raha, Sandeep
Department département
Pediatrics
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Development of a platform for point-of care testing: Accelerating the Assay Pipeline
Keyword
NSERC
Application summary
Evik Diagnostics proposes to engage with Dr. Sandeep Raha, McMaster University, to validate and transfer rapid assay development technologies that will help the company to accelerate new diagnostic tests to market. With assistance from IRAP, Evik has developed simple, low cost, disposable cartridge tests, with all reagents enclosed, that are suitable for deployment in Africa and other resource limited settings. They are similar to a home pregnancy test in simplicity and stability. The first market target for this test device is the growing HIV/AIDS pandemic. Despite 30 years of development effort we do not yet have an HIV vaccine. Worldwide, 34 million are living with AIDS, and 2.5 million new cases are reported each year. The demand for this test device is enormous with hundreds of millions needing screening for new infection, and people living with retroviral therapy needing repeated monitoring for viral load. The test device will report viral load by HIV p24 concentration plus p24 antibodies in blood, a combination method which has been validated to be faster and simpler than DNA tests but in sensitivity. Using microarray high throughput screening, Dr. Raha's lab will test a library of antibodies to find the optimal pair for highest HIV detection sensitivity, and will provide labeled antibody conjugates for the test device. Dr. Raha's lab will transfer the microarray and conjugate chemistry technologies to Evik and vest these rapid assy development tools in the company so that Evik can quickly bring followup diagnostic tests to market. This alliance of complementary technologies will also foster the development of additional diagnostic assays in the future and promote the Canadian Biotechnology industry.